Ability Neurotech announces first-in-human testing of novel BCI technology

Ability Neurotech has conducted first-in-human brain-computer interface testing at Munich's TUM University Hospital, capturing high-resolution neural signals during brain tumour surgery under general anaesthetic. The company plans to progress to neural decoding studies with conscious patients performing speech and motor tasks, establishing a foundation for long-term BCI implantation trials.

This Wire brief sits within Fusion42's coverage of Biotech and Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.